ArticleScientific reports2025
Diagnostic role of galanin in distinguishing endometrial atypical hyperplasia and carcinoma from benign endometrial conditions.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Obesityand Gynaecological Cancers, with a Focus on Morbid Obesity: Risk Stratification, Early Diagnosis and Management.Diagnostics (Basel, Switzerland) · 2026Review
- Galanin Receptors: G Protein-Dependent Signaling and Beyond.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial atypical hyperplasia is recognized as a precursor to endometrial cancer, which ranks as the fourth most common cancer in women and is the leading type of gynecological malignancy in high-income countries. The development and progression of endometrial cancer are strongly linked to increased body fat and insulin resistance. Peptides involved in glucose metabolism, such as leptin, chemerin, and galanin, may contribute to carcinogenesis through shared pathways. This study aims to investigate the role of galanin levels in diagnosing endometrial neoplastic disorders. This prospective case-control study included 85 patients, divided into three groups: endometrial cancer, atypical hyperplasia, and a control group. Serum galanin levels were measured using ELISA across all groups. The mean galanin levels were 472.76 ± 44.86 pg/ml in Control Group, 516.81 ± 51.15 pg/ml in EAH, and 543.15 ± 73.22 pg/ml in Cancer Group. Galanin levels were found to be significantly different among groups. (p < .001) . Galanin levels have the potential to differentiate between normal endometrium and patients with endometrial hyperplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.